Effect of exenatide once weekly on metabolic and glycemic control in patients with prediabetes: a pilot study




Manuel González-Ortiz, Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jal., Mexico
Esperanza Martínez-Abundis, Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jal., Mexico
Karina G. Pérez-Rubio, Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jal., Mexico
Miriam Méndez-del Villar, Institute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Jal., Mexico
Alejandra M. Ramírez-Rodríguez, Institute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Jal., Mexico


Objective: To assess the effect of exenatide once weekly on metabolic and glycemic control in patients with pre diabetes. Methods: This was a quasi-experimental study in eight patients with prediabetes without pharmacological treatment. Exenatide (2 mg) once weekly was administered subcutaneously for 12 weeks. Measurements of metabolic and glycemic control were done before and after pharmacological intervention. Differences at baseline and final measurements were tested using Wilcoxon signed-rank test. P ≤ 0.05 was considered significant. Results: After pharmacological intervention, a significant decrease in body weight (82.5 ± 9.1 vs. 80.6 ± 8.9 kg; p = 0.012), body mass index (31.5 ± 3.7 vs. 30.8 ± 3.7 kg/m2; p = 0.012), waist circumference (101 ± 8 vs. 97 ± 7 cm; p = 0.017), and systolic blood pressure (127 ± 7 vs. 121 ± 7 mmHg; p = 0.021), as well as fasting plasma glucose (6.1 ± 0.4 vs. 5.3 ± 0.9 mmol/l; p = 0.028) and glycated hemoglobin (A1C) (5.7 ± 0.4 vs. 5.4 ± 0.4%; p = 0.046) were observed. Conclusion: Administration of exenatide once weekly for 12 weeks significantly decreases body weight, body mass index, waist circumference and systolic blood pressure as well as fasting plasma glucose and glycated hemoglobin (A1C) in patients with pre diabetes.



Palabras clave: Exenatide. Glycemic control. Metabolic control. Prediabetes.




  •  PDF

  • English version



  •   Agregar a Mendeley